文献速递脑血管病神经重症与神经感染

缺血性卒中取栓后对比剂相关急性肾损伤:预后影响与CAN-REST预测评分

Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive Score.
PubMed 文献 · Neurology · 2026-02-19

这项回顾性多中心队列研究纳入16国73中心2023年取栓治疗的缺血性卒中患者,CA-AKI发生率为4.9%,且与院内死亡、90天mRS评分升高及90天重度残疾或死亡独立相关;基于12项常规术前变量构建的预测模型判别力可接受、校准良好。

要点

  • 取栓患者CA-AKI发生率约4.9%,与院内死亡及90天不良预后独立相关。
  • 12项术前常规变量模型AUC 0.710,校准斜率0.870,Brier评分0.045。
  • 术前评分有助于早期识别高危患者并支持预防策略。

核心结论

  • 在取栓治疗的急性缺血性卒中患者中,CA-AKI发生率约4.9%,且与院内死亡、90天mRS评分升高及90天重度残疾或死亡独立相关。
  • 简单的术前风险评分可早期识别CA-AKI高危个体,可能支持预防策略。

研究设计与样本

  • 回顾性、多中心队列研究,纳入16个国家73个中心2023年1月至12月接受EVT治疗的AIS患者。
  • 纳入标准为年龄≥18岁、非透析、具备术前及术后48小时肌酐值、有90天随访mRS评分,共分析6638例患者(中位年龄74岁,48.7%男性)。

主要发现

  • CA-AKI发生于326例(4.9%)。
  • CA-AKI与院内死亡独立相关(aOR 2.269;95%CI 1.615-3.190)。
  • CA-AKI与90天mRS评分升高独立相关(adjusted common OR 1.584;95%CI 1.110-2.258)。
  • CA-AKI与90天重度残疾或死亡独立相关(aOR 1.530;95%CI 1.057-2.216)。

关键数值与推荐

  • CA-AKI按KDIGO标准定义:48小时内肌酐升高≥0.3 mg/dL或≥基线1.5倍。
  • 术前风险模型含12项常规临床变量:性别、种族、动脉性高血压、血脂异常、慢性肾脏病、抗血小板治疗、入院NIHSS评分、血糖、eGFR、血红蛋白、平均动脉压、静脉溶栓。
  • 模型判别力AUC 0.710(95%CI 0.682-0.738),精确召回曲线下面积0.13(95%CI 0.10-0.16),校准斜率0.870(95%CI 0.759-0.928),Brier评分0.045(95%CI 0.042-0.049)。
  • 纳入EVT相关变量(如对比剂用量)的第二模型表现相似。

临床怎么用

  • 对取栓治疗的AIS患者,可用12项术前常规变量评估CA-AKI风险,早期识别高危个体。
  • 对高危患者可考虑支持预防性策略,并关注院内死亡及90天功能预后。

局限性

  • 原文摘要未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Contrast-associated acute kidney injury (CA-AKI) is a potentially preventable complication after exposure to iodinated contrast media. In patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke (AIS), the incidence and clinical impact are poorly characterized, and no validated prediction tool is currently available. The aim of this study was to assess the incidence and prognostic significance of CA-AKI in EVT-treated patients with AIS and to develop and validate a predictive score. METHODS: A retrospective, multicenter cohort study was conducted involving EVT-treated patients across 73 centers in 16 countries (January-December 2023). Inclusion criteria were age ≥18 years, absence of dialysis, availability of preprocedural and 48-hour postprocedural creatinine levels, and available 90-day follow-up (modified Rankin Scale [mRS] score). The primary outcome was CA-AKI, defined by KDIGO (Kidney Disease: Improving Global Outcomes criteria;creatinine increase ≥0.3 mg/dL or ≥1.5 times baseline, within 48 hours). Secondary outcomes were (1) in-hospital mortality, (2) 90-day mRS score, and (3) 90-day severe disability or death (mRS score >3). Logistic models assessing associations with outcomes accounted for within-center clustering by applying robust standard errors. CA-AKI prediction models were developed across imputed data sets using univariable selection (p < 0.20), backward elimination (p < 0.05), and coefficient-based scoring after categorization of continuous predictors, with internal validation by bootstrap to obtain optimism-adjusted estimates. RESULTS: Among 6,638 patients (median age 74 years; 48.7% male), CA-AKI occurred in 326 (4.9%) and was independently associated with in-hospital mortality (adjusted odds ratio [aOR] 2.269; 95% CI 1.615-3.190), higher 90-day mRS scores (adjusted common odds ratio 1.584; 95% CI 1.110-2.258), and 90-day severe disability or death (aOR 1.530; 95% CI 1.057-2.216). A preprocedural risk model including 12 routine clinical variables-sex, ethnicity, arterial hypertension, dyslipidemia, chronic kidney disease, antiplatelet therapy, NIH Stroke Scale score at admission, serum glucose, estimated glomerular filtration rate, hemoglobin, mean arterial pressure, and IV thrombolysis-demonstrated acceptable discrimination (area under the receiver operating characteristic curve 0.710 [95% CI 0.682-0.738]; precision-recall area under the curve 0.13 [95% CI 0.10-0.16]), good calibration (slope 0.870 [95% CI 0.759-0.928]), good overall performance (Brier score 0.045 [95% CI 0.042-0.049]). A second model that included EVT-related variables (e.g., contrast volume) showed similar performances. DISCUSSION: In this large, international cohort, CA-AKI occurred in approximately 1 in 20 EVT-treated patients with AIS and was independently associated with poor outcomes. A simple preprocedural risk score enables early identification of high-risk individuals and may support preventive strategies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schwarz G, Cascio Rizzo A, Ambler G, et al. Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive Score. Neurology. 2026. PMID: 41712884. doi:10.1212/WNL.0000000000214655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。